Group B streptococci inactivate complement component C5a by enzymic cleavage at the C-terminus
- PMID: 1996961
- PMCID: PMC1149811
- DOI: 10.1042/bj2730635
Group B streptococci inactivate complement component C5a by enzymic cleavage at the C-terminus
Abstract
Incubation of recombinant human C5a (rC5a) with the 7360 strain of group B streptococci (GBS) destroyed the ability of rC5a to stimulate chemotaxis or adherence of purified human polymorphonuclear leucocytes (PMNs). Treatment of 125I-labelled rC5a with GBS 7360 correspondingly decreased rC5a binding to human PMNs. This also resulted in an approx. 600 Da decrease in the molecular mass of rC5a as determined by SDS/PAGE. Incubation of rC5a with the GBS strain GW, which only minimally altered the ability of rC5a to activate human PMNs, did not affect rC5a binding to PMNs and did not alter the molecular mass of rC5a on SDS/PAGE. Plasma-desorption m.s. of rC5a inactivated by GBS 7360 showed that the GBS cleaved the rC5a between histidine-67 and lysine-68 near the C-terminus of rC5a. This mechanism of inactivation of C5a by proteolytic cleavage at the C-terminus of C5a is consistent with the known critical role of the C-terminus in C5a activation of human PMNs. This C5a-cleaving proteinase activity may contribute to the pathophysiology of GBS infections.
Similar articles
-
Restricted ability of group B streptococcal C5a-ase to inactivate C5a prepared from different animal species.Infect Immun. 1993 Apr;61(4):1421-6. doi: 10.1128/iai.61.4.1421-1426.1993. Infect Immun. 1993. PMID: 8454345 Free PMC article.
-
Purification of the proteinase from group B streptococci that inactivates human C5a.Biochim Biophys Acta. 1991 Aug 30;1079(2):222-8. doi: 10.1016/0167-4838(91)90129-n. Biochim Biophys Acta. 1991. PMID: 1911845
-
Group B streptococci inhibit the chemotactic activity of the fifth component of complement.J Immunol. 1988 Nov 15;141(10):3551-6. J Immunol. 1988. PMID: 3053900
-
Role of C5a-ase in group B streptococcal resistance to opsonophagocytic killing.Infect Immun. 1995 Dec;63(12):4764-9. doi: 10.1128/iai.63.12.4764-4769.1995. Infect Immun. 1995. PMID: 7591133 Free PMC article.
-
Bacterial genetics and human immunity to group B streptococci.Mol Genet Metab. 2000 Sep-Oct;71(1-2):451-4. doi: 10.1006/mgme.2000.3025. Mol Genet Metab. 2000. PMID: 11001839 Review.
Cited by
-
The Group A Streptococcal Vaccine Candidate VAX-A1 Protects against Group B Streptococcus Infection via Cross-Reactive IgG Targeting Virulence Factor C5a Peptidase.Vaccines (Basel). 2023 Dec 3;11(12):1811. doi: 10.3390/vaccines11121811. Vaccines (Basel). 2023. PMID: 38140215 Free PMC article.
-
Structural heterogeneity of the streptococcal C5a peptidase gene in Streptococcus pyogenes.J Bacteriol. 2002 Nov;184(22):6384-6. doi: 10.1128/JB.184.22.6384-6386.2002. J Bacteriol. 2002. PMID: 12399509 Free PMC article.
-
Similarity between the group B and A streptococcal C5a peptidase genes.Infect Immun. 1992 Oct;60(10):4239-44. doi: 10.1128/iai.60.10.4239-4244.1992. Infect Immun. 1992. PMID: 1398935 Free PMC article.
-
Genomic and functional determinants of host spectrum in Group B Streptococcus.PLoS Pathog. 2024 Aug 12;20(8):e1012400. doi: 10.1371/journal.ppat.1012400. eCollection 2024 Aug. PLoS Pathog. 2024. PMID: 39133742 Free PMC article.
-
Protease-dependent mechanisms of complement evasion by bacterial pathogens.Biol Chem. 2012 Sep;393(9):873-88. doi: 10.1515/hsz-2012-0174. Biol Chem. 2012. PMID: 22944688 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Molecular Biology Databases